ClinicalTrials.gg
RecruitingNCT04731857EXGEFATUUpdated May 4, 2026

Diagnostic Value of Exome/ Genome Sequencing, Conventional Methods in Rare Diseases and Familial Tumor Syndromes

An observational study in Rare Diseases and Genetic Predisposition, sponsored by University Hospital Tuebingen. Recruiting at 1 site in Germany. Per ClinicalTrials.gov, last updated 2026-05-04.

Sponsored by University Hospital Tuebingen · Observational

How we know

From the registry’s dates

  • Started Feb 2021; still recruiting 5 years 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Retrospective
Enrollment
12,000
Sex
All
01

Study summary

For the retrospective data analysis, patients with genetic diseases of any age and, if available, other family members, for whom genetic analyzes were carried out between 10/2016 and 12/2020, should be included. This equates to approximately 13,000 records, minus combined analyzes in the same patient, an estimated 12,000 individuals.

Read the detailed description

The methodological developments of the last few years allow the broad use of next-generation-sequencing (NGS) -based methods in the routine molecular genetic diagnosis of genetic diseases.The aim of the retrospective data analysis is to create a solid data basis for further discussion regarding the development and mapping of diagnostic algorithms and subsequent supply routes. For the genome data, this evaluation is to be expanded to include the evaluation of the Polygenic risk scores (PRSs) in the sense of an additional finding.

02

Conditions studied

  • Rare Diseases
  • Genetic Predisposition

Keywords

  • Rare Diseases
  • Genetic Predisposition
  • Next Generation Sequencing (NGS)
  • Polygenic risk scores (PRSs)
  • Repeat-Expansion
  • Genetic variation
03

In context

Rare Diseases

592 studies on the registry are indexed under Rare Diseases; 125 are open to participants now.

This study's planned enrollment of 12,000 is above the median of 133 across 208 observational studies indexed under Rare Diseases.

Browse Rare Diseases studies →

Lead sponsor

University Hospital Tuebingen is the lead sponsor of 492 studies on the registry; 110 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

Patients with genetic diseases of any age and, if present, other family members, for whom genetic analyzes were carried out between 10/2016 and 12/2020 at the Institute for Medical Genetics and Applied Genomics at the University Hospital Tübingen.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patient with genetic disease or
  • Family members
  • Genetic analysis between 10/2016 and 12/2020 at the Institute for Medical Genetics and Applied Genomics at the University Hospital Tübingen

Exclusion criteria

Exclusion Criteria:

- None

05

Study design

Observational model
Cohort
Time perspective
Retrospective
Enrollment
12,000 participants (estimated)
Patient registry
No

Groups and cohorts

  • Genetic diseases

    For the retrospective data analysis, patients with genetic diseases of any age and, if available, other family members, for whom genetic analyzes were carried out between 10/2016 and 12/2020, should be included. This equates to approximately 13,000 records, minus combined analyzes in the same patient, an estimated 12,000 individuals.

    Genetic: Retrospective data analysis

Interventions

  • GeneticRetrospective data analysis

    The outlined evaluation contributes to the improvement of molecular genetic diagnostics in patient care - for example when which diagnostics can be sensibly recommended for patients with which indications or not. Diagnostic gaps can be systematically evaluated and specifically addressed in the future. This potentially affects every examination assignment for current and future patients. In addition, the evaluation of the PRSs for example, can contribute significantly to the timely introduction to routine diagnostics. For familial breast cancer, according to the guidelines, there may be very specific preventive measures. Estimates currently assume up to 5% of patients, which would mean up to 25 cases per year with a potentially adapted management for patients with the question of a tumor disease alone.

06

What researchers measure

Primary outcomes

  1. Diagnosis

    Number of established probable diagnosis using molecular genetic diagnostics

    Time frame: Day 1

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Feb 2021 (actual). Primary completion is estimated for Feb 2030, 108 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 26, 2021
First posted
Feb 1, 2021
StartActual
Feb 18, 2021
Primary completionEst.
Feb 2030
CompletionEst.
Feb 2031
Last update
May 4, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 4, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04731857
Responsible party
Sponsor
First posted
Feb 1, 2021
Start date
Feb 18, 2021
Primary completion
Feb 2030 (estimated)
Completion
Feb 2031 (estimated)
Last update
May 4, 2026

Study contacts

Tobias Haack, Dr.
Contact
tobias.haack@med.uni-tuebingen.de
+49 7071 298 ext. 77696
Olaf Rieß, Prof. Dr.
Contact
olaf.riess@med.uni-tuebingen.de
+49 7071 298 ext. 72288
Tobias Haack, Dr.
principal investigator · University Hospital Tübingen

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion